Supernus Pharmaceuticals (SUPN) Operating Expenses (2011 - 2025)

Supernus Pharmaceuticals (SUPN) has 15 years of Operating Expenses data on file, last reported at $215.5 million in Q4 2025.

• On a quarterly basis, Operating Expenses rose 41.08% year-over-year to $215.5 million in Q4 2025; TTM through Mar 2026 was $621.2 million, a 4.67% increase from a year earlier, with the FY2025 full-year figure at $781.2 million, up 34.66% from the prior year.
• Operating Expenses for Q4 2025 stood at $215.5 million, down from $252.3 million in the prior quarter.
• Over the last five years, Operating Expenses for SUPN reached as high as $252.3 million in Q3 2025 and fell as low as $107.2 million in Q2 2021.
• Historically, Operating Expenses has averaged $154.5 million across 5 years, with a median of $151.6 million in 2022.
• Across the five-year window, Operating Expenses dropped 18.52% in 2023 and soared 87.13% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $153.0 million in 2021, then dropped by 13.05% to $133.0 million in 2022, then advanced by 24.3% to $165.3 million in 2023, then fell by 7.6% to $152.8 million in 2024, then surged by 41.08% to $215.5 million in 2025.
• Per Business Quant data, the three most recent Operating Expenses figures were $215.5 million in Q4 2025, $252.3 million in Q3 2025, and $153.3 million in Q2 2025.